AMLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Amylyx Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $-0.67 Mil. Amylyx Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2024 was $1.09 Mil.
The historical data trend for Amylyx Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Receivables Turnover | Get a 7-Day Free Trial | - | - | 1.45 | 13.76 | 4.31 |
Amylyx Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Receivables Turnover | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
3.13 | 2.94 | - | 0.14 | - |
For the Biotechnology subindustry, Amylyx Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Receivables Turnover falls into.
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
Amylyx Pharmaceuticals's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as
Receivables Turnover (A: Dec. 2024 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (A: Dec. 2024 ) | / ( | (Accounts Receivable (A: Dec. 2023 ) | + | Accounts Receivable (A: Dec. 2024 )) | / | count ) |
= | 87.371 | / ( | (40.05 | + | 0.447) | / | 2 ) |
= | 87.371 | / | 20.2485 | ||||
= | 4.31 |
Amylyx Pharmaceuticals's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as
Receivables Turnover (Q: Dec. 2024 ) | |||||||
= | Revenue | / | Average Total Inventories | ||||
= | Revenue (Q: Dec. 2024 ) | / ( | (Accounts Receivable (Q: Sep. 2024 ) | + | Accounts Receivable (Q: Dec. 2024 )) | / | count ) |
= | -0.665 | / ( | (1.731 | + | 0.447) | / | 2 ) |
= | -0.665 | / | 1.089 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (NAS:AMLX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Joshua B Cohen | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Justin B. Klee | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Gina Mazzariello | officer: Chief Legal Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
James M Frates | officer: Chief Financial Officer | 88 SIDNEY ST, CAMBRIDGE MA 021394136 |
Karen Firestone | director | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141 |
Milne George M Jr | director | |
Daphne Quimi | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Patrick D Yeramian | officer: Chief Medical Officer | 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486 |
Morningside Venture Investments Ltd | 10 percent owner | MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
Margaret Olinger | officer: Chief Commercial Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Dragsa 96 Llc | 10 percent owner | 55 RAILROAD AVE., GREENWICH CT 06830 |
Als Invest 1 B.v. | 10 percent owner | EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017 |
Rose Sharon Shabet | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Paul R. Fonteyne | director | C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116 |
From GuruFocus
By GuruFocus News • 11-08-2024
By Business Wire • 03-04-2025
By Business Wire • 10-17-2024
By Business Wire • 02-10-2025
By Business Wire • 12-04-2024
By PRNewswire • 10-03-2024
By Business Wire • 01-06-2025
By GuruFocus News • 11-08-2024
By GuruFocus News • 10-26-2024
By GuruFocus News • 03-05-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.